|Ahead of print publication
N-acetylcysteine maintains penile length and erectile function in bilateral cavernous nerve crush rat model by reducing penile fibrosis
Ming Ma1,2, Chang-Jing Wu1, Peng Zhang1,2, Tao Li1,2, Shan-Zun Wei1,2, Bo-Tao Yu1,2, Feng Qin1, Jiu-Hong Yuan1,2
1 Andrology Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China
2 Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
|Date of Submission||24-Jul-2019|
|Date of Acceptance||20-Jan-2020|
|Date of Web Publication||12-May-2020|
Andrology Laboratory, West China Hospital, Sichuan University, Chengdu 610041; Department of Urology, West China Hospital, Sichuan University, Chengdu 610041
Source of Support: None, Conflict of Interest: None
Penile length shortening and erectile dysfunction are common complications after radical prostatectomy. Various methods have been used to maintain erectile function, but less attention has been paid to preserving penis length. N-acetylcysteine (NAC) has the effect of antioxidation and antifibrotic, which may be beneficial to improve those postoperative complications. This study investigated the effect of NAC on maintaining the penile length and the erectile function after bilateral cavernous nerve crush (BCNC) and its underlying mechanism. Twenty-four male rats were randomly divided into three groups: control group, BCNC group, and BCNC + NAC group. NAC or equal volume of saline was daily administrated by intragastric gavage for 4 weeks. The initial and end penile lengths were measured. Intracavernosal pressure/mean arterial pressure (ICP/MAP) ratio was calculated to assess erectile function. Hematoxylin–eosin staining, Masson's trichrome staining, immunohistochemistry, and Western blot were performed to explore cellular and molecular changes of the penis. Compared to the BCNC group, the penile length, ICP/MAP ratio and smooth muscle/collagen ratio in the BCNC + NAC group were improved significantly (all P < 0.05), and the expressions of endothelial nitric oxide synthase, α-smooth muscle actin, glutathione, and glutathione peroxidase 1 were significantly increased after NAC treated (all P < 0.05), along with the decreased expressions of hypoxia-inducible factor-1α, transforming growth factor-β1, collagen I, collagen III, collagen IV, malonaldehyde, and lysine oxidase (all P < 0.05). This study demonstrated that NAC could maintain penile length and partly improve erectile function. Possible mechanism is directly and/or indirectly related to antihypoxic and antifibrosis.
Keywords: erectile dysfunction; N-acetylcysteine; penile fibrosis; penile length
Article in PDF
|How to cite this URL:|
Ma M, Wu CJ, Zhang P, Li T, Wei SZ, Yu BT, Qin F, Yuan JH. N-acetylcysteine maintains penile length and erectile function in bilateral cavernous nerve crush rat model by reducing penile fibrosis. Asian J Androl [Epub ahead of print] [cited 2020 Jun 6]. Available from: http://www.ajandrology.com/preprintarticle.asp?id=284150
Ming Ma, Chang-Jing Wu
These authors contributed equally to this work.
| Introduction|| |
Prostate cancer is one of the most common malignant tumors in the world, which accounts for 20% of new diagnosed malignant tumors in American men., Radical prostatectomy was widely used in the treatment of localized prostate cancer patients. With the development of pelvic surgical procedures, more and more cavernous nerve-sparing radical prostatectomy has been applied for prostate cancer. Unfortunately, no matter it was robot-assisted, laparoscopic or open surgery, approximately 14%–90% of patients will suffer from new-onset erectile dysfunction (ED), and about 68% patients experience penile length shortening after radical prostatectomy., Currently, various methods have been used to preserve erectile function after radical prostatectomy, such as oral selective phosphodiesterase type 5 inhibitors, vacuum erection device, intracavernous injections, urethral micro-suppository and stem cell therapy.,,, However, less attention was paid to the maintenance of penile length. Phosphodiesterase type 5 inhibitors are currently the most extensively used drugs to preserve erectile function, but the effect of maintaining penis length is unclear., Moreover, multiple studies have confirmed that vacuum erection device can maintain the penile size and incomplete facilitation of erectile function, but the lack of unified operating standards limits its application., Therefore, it is necessary to find a new noninvasiveness and easy-to-operate therapeutic approach to maintain the penile length while maintaining of erectile function.
Previous studies have confirmed that ED and penile length shortening after radical prostatectomy are closely associated with cavernous nerve injury and vascular insufficiency., Vascular insufficiency and the disappearance of spontaneous erection resulted from the imbalance of neurogenic control may result in hypoxia of corpus cavernosum. Long-term hypoxia would increase apoptosis of corpus cavernosum smooth muscle cells, reduce the smooth muscle/collagen ratios, impair endothelial function, and eventually lead to penile fibrosis.,,, Lysine oxidase (LOX) is a critical factor in the deposition of extracellular matrix during fibrosis by catalyzing the oxidative deamination of lysine residues in collagen and elastin. Our previous study has found that anti-LOX therapy by aminopropionitrile could ameliorate penile fibrosis on a rat model of priapism, which is consistent with another study that aminopropionitrile could effectively improve the erectile function by inhibiting fibrosis in bilateral cavernous nerve injury rat model., Also, as the most effective fibrogenic factor, transforming growth factor beta 1 (TGF-β1) has been widely considered to play an important role in penile fibrosis. N-acetylcysteine (NAC), as an acetylated derivative of natural amino acid L-cysteine, is a precursor of glutathione (GSH), which plays an essential role in regulating the redox environment of cells., NAC has antihypoxia, antifibrosis and antioxidation effects, which has been confirmed in cells and organs.,, However, the impact of NAC on penile length and erectile function after radical prostatectomy has not been studied. Based on the effect of NAC and the pathological mechanism of penile length shortening and ED after radical prostatectomy, we assumed that NAC might be a potential drug for the maintenance of erectile function and penile length. In this study, we would like to verify our hypothesis in bilateral cavernous nerve crush (BCNC) rat model and investigate the underlying mechanism.
| Materials and Methods|| |
Twenty-four adult male Sprague–Dawley rats (8 weeks old, 250.00–265.00 g, Chengdu Dossy Experimental Animals, Co., Ltd., Chengdu, China) were housed in cages. All these animals were raised under strict guidelines. Then those 24 rats were randomly divided into three groups after adaptive feeding for 3 days: (1) control group (sham surgery, saline); (2) BCNC group (BCNC surgery, saline); and (3) BCNC + NAC group (BCNC surgery, NAC). The BCNC rat model was based on previous studies. NAC (Hainan Zambon Pharmaceutical Co., Ltd., Haikou, China) was dissolved with normal saline, and the intragastric dose was 500.00 mg kg−1, and 100.00 mg ml−1. NAC or equal volume of saline, which was started on the day after 3 days of BCNC surgery, was daily administrated by intragastric gavage for 4 weeks. The dosage had been fine-tuned based on previous studies. The initial (0 day) and end (28 days) body weight and penis length of rats were measured. The new method for measuring the length of rat penis is based on the method to measure the penis length of newborns and infants. Briefly, a modified 2.5 ml disposable syringe (inner diameter: 9.0 mm) connected to a negative pressure device (Chengdu Xin Wei Cheng Technology Co., Ltd., Chengdu, China), and the flanged end was placed over the penis and firmly pressed onto the pubis. After a unified vacuum (−200 mmHg, 2 min), penile length was recorded, with head of the ruler close to syringe flanged end. All experimental procedures were followed by the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Animal Ethics Committee of West China Hospital, Sichuan University, Chengdu, China (No. 2016057A).
Erectile function evaluation
Erectile function was evaluated in all rats before euthanized. Intracavernosal pressure (ICP) under electric stimulation of the cavernous nerve and mean arterial blood pressure (MAP) were measured by the BL-420F functional biological experiment system (Chengdu TME Technology Co., Ltd., Chengdu, China). Briefly, after being anesthetized with isoflurane inhalation, the cavernous nerve was exposed on the left side of prostate. The left carotid artery was exposed and cannulated with a PE-50 tube to record the MAP. Then, a 24-gauge needle connected to a PE-50 tube and filled with 250.00 U ml−1 heparin sodium solution (Changzhou Qianhong Bio-pharma Co., Ltd., Changzhou, China) was inserted into the left penile crus for measurement of ICP. Stimulation was performed at parameters of 20.0 Hz, 5.0 V, and pulse width of 5.0 ms for 50.0 s. The maximal increase of ICP during electrical nerve stimulation was selected for statistical analysis. The ICP/MAP ratios were analyzed to evaluate the erectile function. After the measurement of erectile function, all penises were harvested from the symphysis pubis for histopathology and molecular assessments.
The Pathology Platform of West China Hospital assisted us in the processing of pathological sections. Briefly, the middle shaft of the penile tissues was rinsed with phosphate buffer solution and fixed in 4.0% paraformaldehyde overnight. After that, these tissues were routinely processed and paraffin embedded. Tissue samples were sliced into 5.0 μm sections. Then, the tissue slides were prepared for hematoxylin-eosin (HE) staining, Masson's trichrome (MT) staining, and immunohistochemistry (IHC). Smooth muscle/collagen ratios were quantitatively analyzed by MT staining (Baso Diagnostics Inc., Zhuhai, China) and those data were collected by Image-Pro Plus 6.0 software (National Institutes of Health, Bethesda, MD, USA). Three sections of each rat were taken for statistical analysis at ×200 magnification, and sections from eight rats per group were analyzed.
IHC was performed for analysis of endothelial nitric oxide synthesis (eNOS), hypoxia-inducible factor-1alpha (HIF-1α), alpha-smooth muscle actin (α-SMA), TGF-β1, LOX, collagen I, collagen III, and collagen IV. The streptavidin-peroxidase method was performed according to the manufacturer's instructions (SP-9000, Beijing ZSbio, Beijing, China). Briefly, samples were treated with 3.0% hydrogen peroxide and blocked by superblock (either 10.0% goat serum or horse serum, depending on the primary antibody) for 30 min at 37°C respectively. Then the sections were incubated with primary antibodies at 4°C for overnight: anti-eNOS (ab76198, 1:100, Abcam, Cambridge, MA, USA), anti-HIF-1α (ab2185, 1:100, Abcam), anti-α-SMA (ab32575, 1:200, Abcam), anti-TGF-β1 (ab92486, 1:100, Abcam), anti-LOX (ab174316, 1:100, Abcam), anticollagen I (ab34710, 1:100, Abcam), anticollagen III (ab7778, 1:100, Abcam), and anticollagen IV (ab6586, 1:100, Abcam). After washing with phosphate buffer solution three times, the sections were incubated with antirabbit or antimouse IgG-conjugated biotin, followed by streptavidin-conjugated horseradish peroxidase. Finally, 3,3'-diaminobenzidine (ZLI-9018, Beijing ZSbio) was used as a chromogen to visualize the positive brown signal. Then the stained sections were counterstained with hematoxylin, dehydrated, and mounted with clear mounting medium. Three sections per rat were quantified at ×200 magnification by Image-Pro Plus 6.0 (Media Cybernetics, Inc., Rockville, MD, USA). Eight rats per group were quantified.
The nerve bundle and urethra were stripped from the corpora before homogenization. Radio immunoprecipitation assay (RIPA) lysis buffer (MA0151, Meilunbio, Dalian, China) containing protease inhibitor cocktail set I (Merck Millipore, Billerica, MA, USA) was added to the corpora cavernosum. The samples were cut and homogenized, and then centrifuged (Sorvall Legend Micro 17R Centrifuge, Thermo Electron LED GmbH, Osterode, Germany) at 12 000g for 20 min at 4°C. Protein concentration was determined by Coomassie brilliant blue G-250 (Amresco Inc., Solon, OH, USA) working buffer. Equal amounts of protein were loaded on 10.0% Tris-glycine gels for electrophoresis. Proteins were wet-transferred to polyvinylidene fluoride membranes (Merck Millipore) and then primary antibodies were used as follows: anti-eNOS (1:1000, Abcam), anti-HIF-1α (1:1000, Abcam), anti-α-SMA (1:1000, Abcam), anti-TGF-β1 (1:1000, Abcam), anti-LOX (ab174316, 1:1000, Abcam), anti-glutathione peroxidase (GPX1; DF6249, 1:1000, Affinity Biosciences, Cincinnati, OH, USA), and anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH; EE0618, 1:2000, Zen BioScience, Chengdu, China). Quantification of eNOS, HIF-1α, α-SMA, TGF-β1, LOX, and GPX1 was performed relative to GAPDH in eight rats per group using Image J 1.46r (National Institutes of Health, Wayne Rasband, MD, USA).
GSH, malonaldehyde (MDA) and LOX activity
GSH and MDA expressions were assessed in rat corpus cavernosum. The expressions were measured with a GSH and MAD assay kit (Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer's instruction. LOX activity was determined using an Amplite TM Fluorimetric Lysyl Oxidase Assay kit (AAT Bioquest Inc., Sunnyvale, CA, USA). Tissues were homogenized in 1.2 mol l−1 urea and 50.0 mmol l−1 sodium borate buffer (pH 8.0). The supernatants were collected after centrifugation (15 000g, 30 min; Sorvall Legend Micro 17R Centrifuge, Thermo Electron LED GmbH). Then, fluorescence was measured using BioTek Synergy Mx (BioTek Instruments Co., Ltd., Winooski, VT, USA) with excitation and emission wavelengths at 560.00 nm and 590.00 nm, respectively. LOX activity was normalized to total protein and expressed as relative fluorescent units per μg protein (RFUs μg−1 protein).
Data were analyzed by GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA, USA) and presented as mean ± standard deviation (s.d.). Statistical differences among multiple groups were compared using the one-way ANOVA analysis, followed with a Tukey test to compare all pairs of columns. For some groups, we performed the Student's t-test to obtain P values. A value of P < 0.05 was considered significant.
| Results|| |
Body weight and penile length
As shown in [Table 1], there was no significant difference in initial body weight (P = 0.1307) or penis length (P = 0.9214) among different groups. Twenty-eight days later, BCNC surgery significantly reduced penis length by 7.28%, but NAC therapy suppressed this reduction (control vs BCNC and BCNC + NAC: 33.25 ± 0.82 mm vs 30.83 ± 1.17 mm and 34.33 ± 1.72 mm, respectively, P <0.05).
|Table 1: Effect of N-acetylcysteine treatment on body weight and penile length|
Click here to view
[Figure 1] shows the results of erectile function. Compared with the BCNC group (0.37 ± 0.03), the ICP/MAP ratio in the NAC treated group (0.49 ± 0.07, P < 0.05) was significantly improved, but it was only partially recovered when compared with the control group (0.66 ± 0.10, P < 0.05).
|Figure 1: Erectile function assessment by ICP tracing under cavernous nerve stimulation. (a) Representative ICP response to cavernous nerve stimulation. (b) Significant differences were found in the ratios of maximum ICP/MAP between the control and BCNC groups, as that between the NAC treatment group and the BCNC group (P <0.05, n = 8 per group). *P <0.05, significant difference. BCNC: bilateral cavernous nerve crush; ICP: intracavernosal pressure; MAP: mean arterial blood pressure; NAC: N-acetylcysteine.|
Click here to view
Smooth muscle/collagen ratio and collagen content
[Figure 2]a shows representative pictures of HE and MT staining in each group. The penile smooth muscle/collagen structure was disordered in the BCNC group, and a large amount of extracellular matrix was deposited. NAC treatment alleviated the above lesions. In [Figure 2]b, the smooth muscle/collagen ratio of the control group was 0.37 ± 0.13, which was significantly higher compared with the BCNC group (0.24 ± 0.07, P <0.05). NAC had improved the rate considerably to 0.35 ± 0.13, which was 48.80% higher than that in the BCNC group (P <0.05).
|Figure 2: NAC therapy preserved penile smooth muscle/collagen ratios. (a) Representative image of hematoxylin-eosin (HE) and Masson's trichrom (MT) staining in each group (×100). (b) MT staining analysis showed that NAC significantly increased the muscle/collagen ratio (P <0.005). (c) Representative photos of collagen I, collagen III, and collagen IV at ×100 magnification. (d) NAC could significantly reduce the expression of collagen I, collagen III and collagen IV in BCNC group (P <0.05). *P <0.05, significant difference. BCNC: bilateral cavernous nerve crush; NAC: N-acetylcysteine; Scale bars = 100μm.|
Click here to view
IHC was performed to assess the expression of collagen content, including collagen I, collagen III, and collagen IV. According to [Figure 2]c and [Figure 2]d, when compared with the control group, the BCNC group had significant increases of collagen I (29.92%, P <0.05), collagen III (38.85%, P <0.05) and collagen IV (98.50%, P <0.05) in corpus cavernosum, while NAC administration could significantly decrease the expression of collagen I (17.61%, P <0.05), collagen III (24.81%, P <0.05), and collagen IV (36.22%, P <0.05).
Expression of eNOS, α-SMA, TGF-β1, and HIF-1α
IHC and Western blot were performed to elucidate the expression of eNOS, α-SMA, TGF-β1, and HIF-1α in corpus cavernosum. Compared with the control group, NAC administration reversed the decreased expression levels of eNOS, α-SMA, and the increased expression of HIF-1α and TGF-β1 (all P <0.05; [Figure 3] and [Supplementary Figure 1[Additional file 1]].
|Figure 3: Western blot analysis. (a) Typical bands of Western blot; bands from up to down represent eNOS, a-SMA, TGF-β1, HIF-1α, and GAPDH. (b) Column figures of eNOS, α-SMA, TGF-β1, and HIF-1α, respectively. Each figure denotes mean ± standard deviation of each protein expression determined by densitometry relative to GAPDH. Compared with the BCNC group, the NAC therapy group significantly increased the expression of eNOS and a-SMA (P <0.05), and decreased the expression of HIF-1α and TGF-β1 (P <0.05). *P <0.05. α-SMA: alpha smooth muscle action; BCNC: bilateral cavernous nerve crush; eNOS: endothelial nitric oxide synthase; GAPDH: glyceraldehyde phosphate dehydrogenase; HIF-1α: hypoxia-inducible factor 1α; NAC: N-acetylcysteine; TGF-β1: transforming growth factor beta 1.|
Click here to view
Expressions of LOX, GPX1, GSH and MDA
Compared to the control group (1.41 ± 0.29), the expression of LOX [Figure 4]a in BCNC group (2.31 ± 0.22, P <0.05) was significantly increased, while NAC reversed the increase (1.77 ± 0.45 vs 2.31 ± 0.22, P <0.05). The altered activity of LOX was consistent with its expression (control: 433.40 ± 187.90 RFUs μg−1 protein, BCNC: 1113.00 ± 181.13 RFUs μg−1 protein, BCNC + NAC: 636.00 ± 206.25 RFUs μg−1 protein; all P <0.05; [Figure 4]b. Besides, the decreased content of GPX1 [Figure 4]c after BCNC operation was reversed by NAC, but there was no significant difference (P = 0.0902). Along with changes of GPX1, NAC treatment (26.90 ± 2.90 μmol g−1) also increased the level of GSH in BCNC group (19.70 ± 3.86 μmol g−1, P <0.05), while that in control group was 28.12 ± 6.36 μmol g−1 (P <0.05) [Figure 4]d. Compared to the BCNC group, the content of MDA was significantly decreased by NAC (control vs BCNC vs BCNC + NAC: 0.61 ± 0.18 nmol g−1vs 1.02 ± 0.45 nmol g−1vs 0.66 ± 0.39 nmol g−1; all P <0.05; [Figure 4]e.
|Figure 4: Oxidative markers for corpus cavernosum. (a) Result of LOX expression of Western blot. (b) LOX enzyme activity. (c) Representative result of GPX1 expression. Protein expression in a and c was determined by densitometry relative to GAPDH. (d) Measurement of GSH. (e) Statistical analysis of MDA. Compared with the BCNC group, the NAC therapy group significantly decreased the expression and activity of LOX (P <0.05). GPX1 had an upward trend after NAC treatment, but there was no statistical difference (P = 0.0902). The over-expression of MDA was significantly reduced (P <0.05), while the expression of GSH was increased (P <0.05). *P <0.05. BCNC: bilateral cavernous nerve crush; GAPDH: glyceraldehyde phosphate dehydrogenase; GPX1: glutathione peroxidase 1; GSH: glutathione; LOX: lysine oxidase; MDA: malonaldehyde; NAC: N-acetylcysteine; RFUs: relative fluorescent units.|
Click here to view
| Discussion|| |
As an animal model simulating the injury of corpus cavernosum nerve caused by radical prostatectomy, BCNC rat model has gradually become a classical model for the study of penile rehabilitation. In this study, penile length and erectile function decreased in the BCNC group, which was consistent with our previous studies.,, Daily administration of NAC maintained penile length after BCNC, and the increased ICP/MAP ratio represented the improvement of erectile function. The expression of eNOS, a key enzyme in nitric oxide synthesis, playing a vital role in penile erectile, was significantly higher in NAC treated group than that in the BCNC group. HE staining showed that the structure of penile cavernosum was disordered with a large amount of extracellular matrix deposition, and the MT staining showed that the smooth muscle/collagen ratio was decreased after BCNC. Moreover, the pathological changes of penile cavernosum fibrosis were correlated with the down-expression of α-SMA and over-expression of hypoxia-related factors, such as TGF-β1, collagens and LOX. Furthermore, the up-regulation of HIF-1α and MDA expression, and the down-regulation of GPX1 and GSH expression suggested that oxidative stress would also be involved in penis shortening and ED after BCNC.
In this study, NAC, a commonly used clinical drug, was proved to be effective in the maintenance of penile length and erectile function after BCNC for the first time. The mechanism may be directly and/or indirectly related to antihypoxic and antifibrosis [Figure 5]. Oxidative stress caused by cavernous nerve injury and hypoxia is closely related to penile fibrosis. In this study, cavernous nerve crush broke the balance between oxidation and antioxidation. MDA, a lipid oxidation production, was increased in BCNC rats. While the main antioxidants, GSH and its catalysis enzyme GPX1, were decreased. GSH is a primary substrate for enzymatic antioxidant functions and is capable of nonenzymatic radical scavenging. The reduced GSH and GPX1 can promote the production of reactive oxygen species (ROS), and the over-expression of ROS can promote the stability and expression of HIF-1α., As a highly conserved transcription factor, HIF-1α can promote the over-expression of other hypoxia-related substrates during hypoxia, such as TGF-β1, LOX and collagen, eventually aggravated penile fibrosis. Besides, HIF-1α can activate target genes and initiate apoptosis, cell death and autophagy., In this study, HIF-1α increased significantly in the BCNC group, while NAC down-regulated the over-expression. Many studies have confirmed that administration of NAC could suppress the ROS-dependent expression of HIF-1α.,, Thus, we speculate that the down-regulation may be attributed to the direct clearance of ROS by GSH, because NAC is a precursor in the formation of the antioxidant GSH. Whether this signaling pathway is involved or not needs to be explored in the follow-up study.
|Figure 5: A possible mechanism of NAC treatment on BCNC rat model. NAC can attenuate HIF-1α mediated hypoxia injury by increasing intracellular GSH, and then down-regulate TGF-β1 and LOX related penile fibrosis. In addition, NAC can directly interfere with the structure and function of TGF-β1 and LOX, and then play the role of antifibrosis. BCNC: bilateral cavernous nerve crush; GSH: glutathione; HIF-1α: hypoxia-inducible factor 1α; LOX: lysine oxidase; NAC: N-acetylcysteine; TGF-β1: transforming growth factor beta1; ROS: reactive oxygen species; GSSG: glutathione disulfide; GPX: glutathione peroxidase.|
Click here to view
Penile fibrosis was thought to play an essential role in the pathological mechanisms of penile length shortening and ED after BCNC. Previous studies have proved that penile vein occlusion resulted from fibrosis leads to the occurrence of ED, and the decreased compliance of cavernous tissue finally leads to the shortening of penile length. Studies have demonstrated that adjuvant administration of NAC is more effective than standard therapy in patients with idiopathic pulmonary fibrosis with retention of vital capacity and single-breath carbon monoxide diffusing capacity., The underlying mechanism might be that NAC significantly inhibited pulmonary fibrosis and improved pulmonary function. In this study, the results of HE, MT and IHC staining also suggested that NAC may ameliorate the structural disorder of corpus cavernosum in BCNC rats by increasing smooth muscle and decreasing collagen components. Therefore, we hypothesized that NAC might retain the erectile function and penis length through a common antifibrotic mechanism.
In recent years, the role of LOX in penile fibrosis has attracted more attention. LOX is an extracellular and copper-dependent monoamine oxidase, which works through catalyzing the crosslinking of lysine residues in collagen and elastin, promoting deposition of collagen and elastin fibers, finally resulting in fibrosis. Studies have demonstrated that LOX plays essential roles in tissue fibrosis, such as myocardium, lung, and liver.,, Our previous study has found that LOX also plays an important role in penile fibrosis in priapism rat model, and aminopropionitrile can improve penile structure and erectile function through anti-LOX and antifibrotic mechanisms, which is consistent with that of Wan et al. Therefore, anti-LOX therapy shows a good prospect in antifibrotic. Unfortunately, aminopropionitrile is a chemical, not being directly applied in clinic. In this study, the penile fibrosis is closely related to the up-regulation of LOX expression and activity, and NAC could down-regulate the expression and activity of LOX to inhibit fibrosis. As discussed above, the down-regulation of HIF-1α can reduce the expression of LOX. Besides, TGF-β1, as an essential activating factor of LOX, whose reduction can lead to the inhibition of LOX expression, was also suppressed by NAC in this study. The increased expression of GSH by NAC may be related to the destruction of the disulphide bond of TGF-β1., Furthermore, as a co-enzyme of LOX, Cu2+ plays a crucial role in the activity of LOX, while GSH can form a complex with the intracellular Cu2+ and transferred to metallothionein. The reduced concentration of Cu2+ and the reduced expression of LOX may attribute to the declined LOX activity.
There are some limitations of this study. NAC can be used in the treatment of a variety of diseases because of its various pharmacological effects. In this study, NAC was administrated by intragastric gavage for 4 weeks. NAC improved the structure of the corpus cavernosum of the penis through antifibrosis and antioxidation, and retained the length and erectile function of the penis. However, it is not clear which is the central role of the above antifibrotic effect. The erectile function was partly maintained, suggesting that NAC may not be used alone, but may become an important auxiliary drug for other penile rehabilitation therapy. Moreover, it is regretful that we only focused on the effects of NAC on penile cavernosum, but did not detect the effect of NAC on the repair or regeneration of the injured cavernous nerve. In the follow-up experiments, further studies are needed to explore the molecular mechanism in more detail, and explain whether NAC has an impact on the structure and function of the nerve, and explore its mechanism.
| Author Contributions|| |
MM, CJW, and PZ carried out the experiments. MM and CJW contributed to the statistical analyses and the manuscript preparation. BTY, SZW, and FQ participated in the article screening, and critical revision of the manuscript. MM, CJW, PZ and TL participated in the experiments design. JHY conceived of this study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
| Competing Interests|| |
All authors declare no competing interests.
| Acknowledgments|| |
This work was supported by the Natural Science Foundation of China (No. 81671453 and No. 81871147), the Sichuan Science and Technology Program (No. 2018SZ0019 and No. 2018TJPT0018).
Supplementary Information is linked to the online version of the paper on the Asian Journal of Andrology website.
| References|| |
Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, et al.
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin
2010; 60: 70–98.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin
2019; 69: 7–34.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, et al.
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol
2017; 71: 618–29.
Mullerad M, Donohue JF, Li PS, Scardino PT, Mulhall JP. Functional sequelae of cavernous nerve injury in the rat: is there model dependency. J Sex Med
2006; 3: 77–83.
Clavell-Hernandez J, Wang R. The controversy surrounding penile rehabilitation after radical prostatectomy. Transl Androl Urol
2017; 6: 2–11.
Montorsi F, Oelke M, Henneges C, Brock G, Salonia A, et al.
Exploratory decision-tree modeling of data from the randomized REACTT trial of tadalafil versus placebo to predict recovery of erectile function after bilateral nerve-sparing radical prostatectomy. Eur Urol
2016; 70: 529–37.
Raina R, Agarwal A, Ausmundson S, Lakin M, Nandipati KC, et al.
Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res
2006; 18: 77–81.
Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. A review of outcomes of an intracavernosal injection therapy programme. BJU Int
2012; 110: 1787–91.
Yiou R, Hamidou L, Birebent B, Bitari D, Lecorvoisier P, et al.
Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol
2016; 69: 988–91.
Ahmed K, Hatzimouratidis K, Muneer A. Male sexual dysfunction and hypogonadism guidelines for the aging male. Eur Urol Focus
2017; 3: 514–6.
Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, et al.
Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol
2012; 62: 273–86.
Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med
2005; 2: 658–67.
Kohler TS, Pedro R, Hendlin K, Utz W, Ugarte R, et al.
A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int
2007; 100: 858–62.
Raina R, Pahlajani G, Agarwal A, Jones S, Zippe C. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int
2010; 106: 1719–22.
Burnett AL. Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy. Urology
2003; 61: 491–7.
Qian SQ, Gao L, Wei Q, Yuan J. Vacuum therapy in penile rehabilitation after radical prostatectomy: review of hemodynamic and antihypoxic evidence. Asian J Androl
2016; 18: 446–51.
Qian SQ, Qin F, Zhang S, Yang Y, Wei Q, et al.
Vacuum therapy prevents corporeal veno-occlusive dysfunction and penile shrinkage in a cavernosal nerve injured rat model. Asian J Androl
2020; 22: 274–9.
Yuan J, Lin H, Li P, Zhang R, Luo A, et al.
Molecular mechanisms of vacuum therapy in penile rehabilitation: a novel animal study. Eur Urol
2010; 58: 773–80.
Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, et al.
Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J Clin Invest
1993; 91: 437–42.
Lin H, Yuan J, Ruan KH, Yang W, Zhang J, et al.
COX-2-10aa-PGIS gene therapy improves erectile function in rats after cavernous nerve injury. J Sex Med
2013; 10: 1476–87.
Reiser K, McCormick RJ, Rucker RB. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J
1992; 6: 2439–49.
Gao L, Wu C, Fu F, You X, Ma X, et al.
Effect of lysyl oxidase (LOX) on corpus cavernous fibrosis caused by ischaemic priapism. J Cell Mol Med
2018; 22: 2018–22.
Wan ZH, Li GH, Guo YL, Li WZ, Chen L, et al.
Amelioration of cavernosal fibrosis and erectile function by lysyl oxidase inhibition in a rat model of cavernous nerve injury. J Sex Med
2018; 15: 304–13.
Nehra A, Gettman MT, Nugent M, Bostwick DG, Barrett DM, et al.
Transforming growth factor-beta1 (TGF-beta1) is sufficient to induce fibrosis of rabbit corpus cavernosum in vivo
. J Urol
1999; 162: 910–5.
Liao W, Xiang W, Wang FF, Wang R, Ding Y. Curcumin inhibited growth of human melanoma A375 cells via inciting oxidative stress. Biomed Pharmacother
2017; 95: 1177–86.
Meurer SK, Lahme B, Tihaa L, Weiskirchen R, Gressner AM. N-acetyl-L-cysteine suppresses TGF-beta signaling at distinct molecular steps: the biochemical and biological efficacy of a multifunctional, antifibrotic drug. Biochem Pharmacol
2005; 70: 1026–34.
Yi Z, Jiang L, Zhao L, Zhou M, Ni Y, et al.
Glutathione peroxidase 3 (GPX3) suppresses the growth of melanoma cells through reactive oxygen species (ROS)-dependent stabilization of hypoxia-inducible factor 1-alpha and 2-alpha. J Cell Biochem
2019; 120: 19124–36.
Li S, Yang X, Li W, Li J, Su X, et al.
N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats. Respiration
2012; 84: 509–17.
Kopp J, Seyhan H, Muller B, Lanczak J, Pausch E, et al.
N-acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-beta signalling. J Cell Mol Med
2006; 10: 157–65.
Quinlan DM, Nelson RJ, Partin AW, Mostwin JL, Walsh PC. The rat as a model for the study of penile erection. J Urol
1989; 141: 656–61.
Ozbey H, Temiz A, Salman T. A simple method for measuring penile length in newborns and infants. BJU Int
1999; 84: 1093–4.
Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med
2007; 4: 908–16.
Yang L, Tan P, Zhou W, Zhu X, Cui Y, et al.
N-acetylcysteine protects against hypoxia mimetic-induced autophagy by targeting the HIF-1alpha pathway in retinal ganglion cells. Cell Mol Neurobiol
2012; 32: 1275–85.
Wu CH, Tang SC, Wang PH, Lee H, Ko JL. Nickel-induced epithelial-mesenchymal transition by reactive oxygen species generation and E-cadherin promoter hypermethylation. J Biol Chem
2012; 287: 25292–302.
Garcia-Trevijano ER, Iraburu MJ, Fontana L, Dominguez-Rosales JA, Auster A, et al.
Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology
1999; 29: 960–70.
Jan YH, Lai TC, Yang CJ, Lin YF, Huang MS, et al.
Adenylate kinase 4 modulates oxidative stress and stabilizes HIF-1alpha to drive lung adenocarcinoma metastasis. J Hematol Oncol
2019; 12: 12.
Heil J, Schultze D, Schemmer P, Bruns H. N-acetylcysteine protects hepatocytes from hypoxia-related cell injury. Clin Exp Hepatol
2018; 4: 260–6.
Qin W, Li C, Zheng W, Guo Q, Zhang Y, et al.
Inhibition of autophagy promotes metastasis and glycolysis by inducing ROS in gastric cancer cells. Oncotarget
2015; 6: 39839–54.
Huang KT, Wu CT, Huang KH, Lin WC, Chen CM, et al.
Titanium nanoparticle inhalation induces renal fibrosis in mice via an oxidative stress upregulated transforming growth factor-beta pathway. Chem Res Toxicol
2015; 28: 354–64.
O'Leary AJ, Drummond SE, Edge D, O'Halloran KD. Diaphragm muscle weakness following acute sustained hypoxic stress in the mouse is prevented by pretreatment with N-acetyl cysteine. Oxid Med Cell Longev
2018; 2018: 4805493.
Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther
2014; 141: 150–9.
Ciancio SJ, Kim ED. Penile fibrotic changes after radical retropubic prostatectomy. BJU Int
2000; 85: 101–6.
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, et al.
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med
2005; 353: 2229–42.
Lopez B, Gonzalez A, Hermida N, Valencia F, de Teresa E, et al.
Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol
2010; 299: H1–9.
Nave AH, Mizikova I, Niess G, Steenbock H, Reichenberger F, et al.
Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol
2014; 34: 1446–58.
Liu SB, Ikenaga N, Peng ZW, Sverdlov DY, Greenstein A, et al.
Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. FASEB J
2016; 30: 1599–609.
White AC, Maloney EK, Lee SL, Lanzillo JJ, Fanburg BL. Reduction of endothelial cell related TGFbeta activity by thiols. Endothelium
1999; 6: 231–9.
Saporito-Magrina CM, Musacco-Sebio RN, Andrieux G, Kook L, Orrego MT, et al.
Copper-induced cell death and the protective role of glutathione: the implication of impaired protein folding rather than oxidative stress. Metallomics
2018; 10: 1743–54.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]